MSCs migrate towards breast cancer cells via hypoxia-induced interleukin 6 (IL6) secretion [47] and towards primary breast tumors via the hypoxia-inducible factor alpha (HIFα)-dependent secretion of CXCL16 [48]. Here, IL6 is linked to breast neoplasm.